



ASX ANNOUNCEMENT

Lumos Q3 FY26 Reporting Date, Webinar Invitation and SPP Reminder

Key Highlights

- Lumos to report Q3 FY26 results on Monday, 20 April 2026
- Investors invited to attend webinar on Tuesday, 21 April 2026
- Share Purchase Plan reminder – closes at 5pm (AEST) on 24 April 2026, with one free attaching option for every two shares subscribed for
- SPP resources available to investors via <https://lumosdiagnostics.com/invest>

MELBOURNE, Australia (15 April 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”), a leader in rapid, point-of-care diagnostic technologies, is pleased to announce its Q3 FY26 reporting date; invite investors to the quarterly investor briefing and provide a resources link for the Company’s Share Purchase Plan (“SPP”), which opened on 10 April 2026.

Share Purchase Plan - Reminder and Resources

Lumos is pleased to invite eligible shareholders to participate in the Company’s SPP and Options Offer which opened last Friday, 10 April 2026, **with one free attaching option for every two SPP shares subscribed for**. The SPP is being offered to eligible shareholders on the same terms as the recent Placement to existing and new sophisticated and institutional investors (ASX: 27 March 2026).

Key resources for shareholders, including the Prospectus, Target Market Determination, Investor Presentation, Use of Funds and Timetable are all available via: <https://lumosdiagnostics.com/invest>. The SPP will close on Friday, 24 April 2026 at 5.00pm (AEST).

Q3 FY26 Results - Release and Webinar Info

Lumos plans to release its Q3 FY26 results on Monday, 20 April 2026. The Company invites investors and analysts to attend its Q3 FY26 results webinar, to be held online on Tuesday, 21 April 2026 at 11:00am (AEST.)

Participants can register ahead of time, via the following link:

https://us02web.zoom.us/webinar/register/WN_LGuVX42cSH6Fq0asH0O5uw

Once the registration form is complete, investors will receive a confirmation email with details on how to access the meeting. The Lumos team looks forward to welcoming all those who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics,

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598